ClinicalTrials.gg
TerminatedNCT03154333Updated Nov 5, 2019Results posted

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

A Phase 2 interventional study of diacerein 1% ointment and A placebo ointment in Epidermolysis Bullosa Simplex, sponsored by Castle Creek Pharmaceuticals, LLC. Terminated at 22 sites in 8 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2019-11-05.

Sponsored by Castle Creek Pharmaceuticals, LLC · Phase 2, Interventional, and Treatment

Why this study was terminated
Futility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Epidermolysis Bullosa Simplex with a site in United States — 3 open to participants now, 4 under way, 1 of them phase 3. Epidermolysis Bullosa Simplex · United States.

Started
2017
with 2 others
Phase 2
5 of 11
2 open now
Registered
3rd of 11
by date
Lead sponsor
3 of 11
Castle Creek Pharmaceuticals, LLC

Among the 11 studies in Epidermolysis Bullosa Simplex with a site in United States, this one is one of 3 that started in 2017, is one of 5 in phase 2, and was the 3rd registered.

Epidermolysis Bullosa Simplex

20 studies on the registry are indexed under Epidermolysis Bullosa Simplex; 5 are open to participants now.

Browse Epidermolysis Bullosa Simplex studies →

Open to participants now

3 of the 11 studies in Epidermolysis Bullosa Simplex with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Epidermolysis Bullosa Simplex studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Epidermolysis Bullosa Simplex with a site in United States, or all of them as a file.
02

Study summary

Epidermolysis bullosa simplex (EBS) is a rare genetic skin disease characterized by fragility of the skin and mucous membranes resulting in painful blisters and erosions after minor trauma. The purpose of this study is to compare the efficacy of diacerein 1% ointment to vehicle ointment when applied once-daily for 8 weeks in subjects with EBS.

Read the detailed description

The study is an international, multicenter, randomized, double-blind, vehicle-controlled, parallel group study to evaluate the safety and efficacy of diacerein 1% ointment for the treatment of subjects with EBS. Participants were assigned to study groups receiving either diacerein 1% ointment or vehicle ointment for 8 weeks, followed by an 8 week follow-up period. Approximately 80 subjects were to be randomized to one of the 2 treatment groups.

The primary objective of this study is to compare the efficacy of diacerein 1% ointment to vehicle ointment based on reduction in body surface area (BSA) of EBS lesions being treated when applied once-daily for 8 weeks in subjects with EBS. The secondary objectives are to compare the effects of diacerein 1% ointment to vehicle ointment in subjects with EBS in changes in Investigator Global Assessment (IGA) scores, pain, pruritus, mobility, and safety and tolerability.

03

Conditions studied

  • Epidermolysis Bullosa Simplex

Keywords

  • Epidermolysis
  • bullosa
  • simplex
  • EBS
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subject is at least 4 years of age at Screening
  • Subject has a documented genetic mutation consistent with EBS. Gene mutations acceptable for inclusion are as follows: KRT5, KRT14, PLEC1, TGM5, PKP1, DSP, FERMT1, EXPH5, DST, KLHL24.
  • Subject has an Assessment Area of EBS lesions to be treated, that is ≥2% body surface area (BSA) and the EBS lesions are in one or both of the following body areas:

    • Localized: plantar and/or palmar areas
    • Generalized: arms, legs, torso, hands and feet
  • Subject's EBS lesions in the Assessment Area have an Investigator's Global Assessment (IGA) score of ≥3
  • Subject/caregiver agrees to not use any topical therapies other than the study medication that might influence the status of the EBS lesions during the duration of the study
  • Subject is non-pregnant as confirmed by a negative urine pregnancy screen, non-lactating and is not planning for pregnancy during the study period
  • If the subject is a woman of , agrees to use an approved effective method of
  • Subject is in good general health and free of any known disease state or physical condition which might impair evaluation of the EBS lesions or which exposes the subject to an unacceptable risk by study participation

Key Exclusion Criteria:

  • Subject has EBS lesions to be treated that are infected
  • Subject has used any diacerein containing product within 6 months prior to Screening
  • Subject has used systemic immunotherapy or cytotoxic chemotherapy within 60 days prior to Screening
  • Subject has used systemic steroidal therapy or has used topical steroidal therapy on the EBS lesions to be treated within 30 days prior to Baseline
  • Subject has evidence of a systemic infection or has used systemic antibiotics within 7 days prior to Screening
  • Subject is currently using systemic analgesics and/or anti-histamine therapy, for treatment of EBS lesions unless on a stable regimen (i.e., the same dosing regimen) for at least 4 weeks prior to Screening
  • Subject has used any systemic diuretics or cardiac glycosides or any systemic product that might put the subject at undue risk
  • Subject has used any topical product containing allantoin on the EBS lesions to be treated within 30 days prior to Screening
  • Subject has a current , or a history of treatment for a malignancy within 2 years prior to Screening
  • Subject currently has diabetes mellitus ( ≥6.5%) or controlled diabetes (HbA1c \< 6.5%)
  • Subject has a history of cardiac, hepatic ( and or AST >2x , Total >1.5x ULN at Screening), or renal disease (\<30 ml/min/1.73 m\^2)
  • Subject has a non-EBS skin disease or condition (e.g., sunburn) that might put the subject at undue risk by study participation or interferes with the study medication application or the study assessments
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    diacerein 1% ointment

    diacerein 1% ointment will be used for 8 weeks

    Drug: diacerein 1% ointment

  • Placebo comparator
    vehicle ointment

    vehicle ointment will be used for 8 weeks

    Drug: A placebo ointment

Interventions

  • diacerein 1% ointment administered topically

    Also known as: CCP-020

  • DrugA placebo ointment

    vehicle ointment administered topically

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects Who Achieved ≥ 60% Reduction in Body Surface Area (BSA) of EBS Lesions Within Assessment Area

    Analysis of the proportion of subjects who achieved a ≥60% reduction in Body Surface Area (BSA) of EBS lesions within Assessment Area from Baseline to Week 8

    Time frame: Baseline to Week 8

Secondary outcomes

  1. The Proportion of Subjects Who Achieved Success on the Investigator's Global Assessment (IGA)

    The investigator's global assessment (IGA) is a five-point scale that is used for overall clinical assessment of severity of disease and classifies EBS-involved skin with a score ranging from 0-4. Success on the IGA was defined as ≥2-point reduction from Baseline to Visit 6 (Week 8). IGA Scoring: 0 = Clear; 1 = Near Clear; 2 = Mild; 3 = Moderate; 4 = Severe Minimum score = 0 Maximum score = 4; higher score = worse outcome

    Time frame: Baseline to Week 8

07

Results

Posted Nov 5, 2019

Participant flow

Participant flow — Overall Study
MilestoneDiacerein 1% OintmentVehicle Ointment
Started2826
Completed2121
Not completed75

Outcome measures

PrimaryProportion of Subjects Who Achieved ≥ 60% Reduction in Body Surface Area (BSA) of EBS Lesions Within Assessment Area

Analysis of the proportion of subjects who achieved a ≥60% reduction in Body Surface Area (BSA) of EBS lesions within Assessment Area from Baseline to Week 8

Time frame:
Baseline to Week 8
Reported as:
Count of participants · Participants
Proportion of Subjects Who Achieved ≥ 60% Reduction in Body Surface Area (BSA) of EBS Lesions Within Assessment Area
ParticipantsDiacerein 1% OintmentVehicle Ointment
Proportion of Subjects Who Achieved ≥ 60% Reduction in Body Surface Area (BSA) of EBS Lesions Within Assessment Area1614
Statistical analysis
  • Diacerein 1% Ointment vs Vehicle Ointment · Cochran-Mantel-Haenszel · p = 0.9666 · Risk ratio (rr): 1.01 · 95% CI 0.63 to 1.62Log transformation normalized the Risk Ratio (RR) estimates; the Standard Error (SE) of the estimate was obtained from confidence limits for the RR.
SecondaryThe Proportion of Subjects Who Achieved Success on the Investigator's Global Assessment (IGA)

The investigator's global assessment (IGA) is a five-point scale that is used for overall clinical assessment of severity of disease and classifies EBS-involved skin with a score ranging from 0-4. Success on the IGA was defined as ≥2-point reduction from Baseline to Visit 6 (Week 8). IGA Scoring: 0 = Clear; 1 = Near Clear; 2 = Mild; 3 = Moderate; 4 = Severe Minimum score = 0 Maximum score = 4; higher score = worse outcome

Time frame:
Baseline to Week 8
Reported as:
Count of participants · Participants
The Proportion of Subjects Who Achieved Success on the Investigator's Global Assessment (IGA)
ParticipantsDiacerein 1% OintmentVehicle Ointment
The Proportion of Subjects Who Achieved Success on the Investigator's Global Assessment (IGA)127
Statistical analysis
  • Diacerein 1% Ointment vs Vehicle Ointment · Cochran-Mantel-Haenszel · p = 0.2861 · Risk ratio (rr): 1.53 · 95% CI 0.41 to 3.28Log transformation normalized the Risk Ratio (RR) estimates; the Standard Error (SE) of the estimate was obtained from confidence limits for the RR.

Adverse events

Collected over Baseline to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Diacerein 1% Ointment0/28 (0%)0/28 (0%)16/28 (57.1%)
Vehicle Ointment0/26 (0%)2/26 (7.7%)15/26 (57.7%)
Most frequent serious events
Most frequent serious events
EventDiacerein 1% OintmentVehicle Ointment
Humerus fractureInjury, poisoning and procedural complications0/281/26
Meniere's DiseaseEar and labyrinth disorders0/281/26
Most frequent other events
Showing 10 of 18
Most frequent other events
EventDiacerein 1% OintmentVehicle Ointment
NasopharyngitisInfections and infestations4/282/26
VomitingGastrointestinal disorders4/281/26
CoughRespiratory, thoracic and mediastinal disorders4/281/26
Skin InfectionInfections and infestations3/283/26
HeadacheNervous system disorders1/283/26
FallInjury, poisoning and procedural complications0/283/26
DiarrhoeaGastrointestinal disorders3/280/26
PruritusSkin and subcutaneous tissue disorders3/281/26
Viral Upper Respiratory Tract InfectionInfections and infestations2/282/26
Upper Respiratory Tract InfectionInfections and infestations1/282/26

Baseline characteristics

All efficacy endpoints were based on the Assessment Area, defined in the protocol, unless otherwise stated. The Intent to Treat (ITT) Population was used for these analyses.

Age, Customized
Age, Customized(Participants)Diacerein 1% OintmentVehicle OintmentTotal
Age <8 years old131225
Age greater than or equal to 8 years old151429
Sex: Female, Male
Sex: Female, Male(Participants)Diacerein 1% OintmentVehicle OintmentTotal
Female141630
Male141024
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Diacerein 1% OintmentVehicle OintmentTotal
American Indian or Alaska Native000
Asian202
Native Hawaiian or Other Pacific Islander000
Black or African American011
White242347
More than one race000
Unknown or Not Reported224
Baseline BSA(Body Surface Area) of EBS(Epidermolysis Bullosa Simplex) Lesions within Assessment Area
Baseline BSA(Body Surface Area) of EBS(Epidermolysis Bullosa Simplex) Lesions within Assessment Area(Percent of BSA)Diacerein 1% OintmentVehicle OintmentTotal
Mean5.76 ± 4.6747.13 ± 7.6066.42 ± 6.237
Baseline IGA Score of 3 or 4
Baseline IGA Score of 3 or 4(Participants)Diacerein 1% OintmentVehicle OintmentTotal
IGA Score: 3262450
IGA Score: 4224
08

Study locations

22 sites
  • Phoenix Childrens Hospital
    Phoenix, Arizona 85016, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Ann and Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • University of Missouri Healthcare
    Columbia, Missouri 65212, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11790, United States
  • University of North Carolina - Chapel Hill
    Chapel Hill, North Carolina 27516, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425-5780, United States
  • Children's Hospital of San Antonio ; Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Premier Specialists Pty Ltd; The Church
    Kogarah, New South Wales 2217, Australia
  • EB House Austria
    Salzburg, A-5020, Austria
  • Hopital Saint Louis
    Paris, Cedex 75010, France
  • Hopital Necker-Enfants Malades
    Paris, Cedex 75015, France
  • CHU de NICE - Hopital de l'Archet II - Service de Dermatologie
    Nice, 06202, France
  • University Medical Center Freiburg
    Freiburg im Breisgau, 79104, Germany
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • University Medical Center Groningen
    Groningen, AB20;30,001, Netherlands
  • Great Ormond Street Hospital
    London, England WC1N 3JH, United Kingdom
  • St. Thomas' Hospital - St Johns Institute of Dermatology
    London, SE1 7EH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Oct 2018, 16 months.

Results were first posted in Nov 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2017
First posted
May 16, 2017
StartActual
Jun 1, 2017
Primary completionActual
Oct 15, 2018
CompletionActual
Oct 31, 2018
Results first posted
Nov 5, 2019
Last update
Nov 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03154333
Lead sponsor
Castle Creek Pharmaceuticals, LLC
Responsible party
Sponsor
First posted
May 16, 2017
Start date
Jun 1, 2017
Primary completion
Oct 15, 2018
Completion
Oct 31, 2018
Results posted
Nov 5, 2019
Last update
Nov 5, 2019

Study contacts

Mary Spellman, MD
study director · Castle Creek Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diacerein

Start the discussion